ALEC Alector Inc

Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that management will participate in the following upcoming investor conferences:

• Bank of America Securities Health Care Conference (Las Vegas, Nevada)
  • Tuesday, May 14, 2024, at 8:55 a.m. PT, corporate presentation
• H.C. Wainwright 2nd Annual BioConnect Investor Conference (New York, New York)
  • Monday, May 20, 2024, at 11:00 a.m. ET, fireside chat

A webcast of each conference presentation will be available on the “Events & Presentations” page within the Investors section of the Alector website at http://investors.alector.com. Replays of the webcasts will be available on the Alector website for 90 days following the presentation dates.

About AlectorAlector is a clinical-stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Immuno-neurology targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. Alector has discovered and is developing a broad portfolio of innate immune system programs, designed to functionally repair genetic mutations that cause dysfunction of the brain’s immune system and enable rejuvenated immune cells to counteract emerging brain pathologies. Alector’s immuno-neurology product candidates are supported by biomarkers and seek to treat indications, including Alzheimer’s disease and genetically defined frontotemporal dementia patient populations. Alector is headquartered in South San Francisco, California.

Alector Contacts: AlectorKatie Hogan202-549-0557katie.hogan@alector.com

1AB (media) Dan Budwick 973-271-6085 dan@1abmedia.com

Argot Partners (investors)Laura Perry212.600.1902alector@argotpartners.com